Recent advances in dermatology.

[1]  W. Holcomb,et al.  African-American women have higher initial HbA1c levels in diabetic pregnancy. , 2001, Diabetes care.

[2]  David G Armstrong,et al.  Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. , 2001, Diabetes care.

[3]  I. Bekersky,et al.  Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. , 2001, Journal of the American Academy of Dermatology.

[4]  R. Langley,et al.  Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. , 2001, Journal of the American Academy of Dermatology.

[5]  A. Paller,et al.  A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. , 2001, Journal of the American Academy of Dermatology.

[6]  D. Leung,et al.  Cellular and immunologic mechanisms in atopic dermatitis. , 2001, Journal of the American Academy of Dermatology.

[7]  P. Nghiem.  "Topical immunomodulators?": introducing old friends and a new ally, tacrolimus. , 2001, Journal of the American Academy of Dermatology.

[8]  Sewon Kang,et al.  Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. , 2001, Journal of the American Academy of Dermatology.

[9]  A. Fleischer,et al.  Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. , 2001, Journal of the American Academy of Dermatology.

[10]  Aditya K. Gupta,et al.  Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. , 2000, Journal of the American Academy of Dermatology.

[11]  Aditya K. Gupta,et al.  Ciclopirox nail lacquer solution 8% in the 21st century. , 2000, Journal of the American Academy of Dermatology.

[12]  M. Bohn,et al.  Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. , 2000, Journal of the American Academy of Dermatology.

[13]  Aditya K. Gupta,et al.  Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. , 2000, Journal of the American Academy of Dermatology.

[14]  M. Dahl,et al.  Imiquimod: an immune response modifier. , 2000, Journal of the American Academy of Dermatology.

[15]  D. Sauder,et al.  Immunomodulatory and pharmacologic properties of imiquimod. , 2000, Journal of the American Academy of Dermatology.

[16]  B. Piraccini,et al.  Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. , 2000, Journal of the American Academy of Dermatology.

[17]  K. Beutner,et al.  Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. , 1999, Journal of the American Academy of Dermatology.

[18]  L. Edwards.  Imiquimod in clinical practice. , 1998, The Australasian journal of dermatology.

[19]  J. Smiell,et al.  Efficacy and Safely of a Topical Gel Formulation of Recombinant Human Platelet-Derived Growth Factor-BB (Becaplermin) in Patients With Chronic Neuropathic Diabetic Ulcers: A phase III randomized placebo-controlled double-blind study , 1998, Diabetes Care.

[20]  I. Orengo,et al.  Anti‐inflammatory activity of antifungal preparations , 1997, International journal of dermatology.

[21]  H. Degreef,et al.  Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. , 1997, Journal of the American Academy of Dermatology.

[22]  D. Steed,et al.  Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. , 1996, Journal of the American College of Surgeons.

[23]  G. Weidinger,et al.  Terbinafine in onychomycosis with involvement by non‐dermatophytic fungi , 1994, The British journal of dermatology.